CytomX and Unicycive Therapeutics report business and financial updates

CytomX Therapeutics has received a rating upgrade from Wall Street Zen, which moved the stock from a ‘sell’ to a ‘hold’ rating. Other recent analyst actions include Wolfe Research initiating coverage with an ‘outperform’ rating and a $6.00 price target, while Guggenheim adjusted its price target from $15.00 to $14.00 with a ‘buy’ rating. The company currently holds a consensus rating of ‘Buy’ with an average price target of $11.90.

Unicycive Therapeutics announced its second quarter 2026 financial results, reporting $61.4 million in unaudited cash, cash equivalents, and marketable securities, which the company expects will provide a runway into 2027. Following a Complete Response Letter from the FDA regarding its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the company is preparing to resubmit the application once a scheduled FDA facility inspection of its third-party manufacturing vendor is completed.